Get Full Government Meeting Transcripts, Videos, & Alerts Forever!
Kansas committee hears sharply divided testimony on HB2550 requiring 340B hospital reporting
Summary
Supporters said HB2550 would add needed transparency to the federal 340B drug‑pricing program so policymakers can see whether savings reach vulnerable patients; hospitals and rural pharmacists called the measure duplicative, one‑sided and administratively burdensome.
The Committee on Insurance heard more than three hours of testimony on House Bill 2550, a proposal to require hospitals that participate in the federal 340B drug‑pricing program to file annual reports with the Kansas Department of Insurance detailing savings, how the savings are used and drug acquisition and payment data.
Eileen, a committee staffer, told members the bill would require hospitals, beginning Jan. 1, 2027, to report items including estimated annual savings from 340B participation, how those savings are used, a comparison of 340B savings to the hospital’s total drug spending, aggregated acquisition costs for drugs obtained under 340B, aggregate payment amounts received and the number of pricing units dispensed. The bill also grants the insurance commissioner rulemaking authority.
Supporters described the measure as a modest transparency step. “When cost rise or access is disrupted, the consequence can include relapse, hospitalization, or even loss of life,”…
Already have an account? Log in
Subscribe to keep reading
Unlock the rest of this article — and every article on Citizen Portal.
- Unlimited articles
- AI-powered breakdowns of topics, speakers, decisions, and budgets
- Instant alerts when your location has a new meeting
- Follow topics and more locations
- 1,000 AI Insights / month, plus AI Chat
